Trial · NCT06558773
GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.
NCT06558773, Phase 2, Recruiting, Chinese PLA General Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC. Trials, record NCT06558773. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06558773
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.
- NCT number
- NCT06558773
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 120 participants, estimated
- Lead sponsor
- Chinese PLA General Hospital
- Conditions
- Colorectal Cancer
- Interventions
- Regorafenib+Immune checkpoint inhibitor, Eliglustat+Immune checkpoint inhibitor, Eliglustat+Immune checkpoint inhibitor +Regorafenib
- First posted
- 2024-08-19
- Last updated
- 2026-02-11
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate (ORR) | Up to 120 days after the last dose of study drugs | Objective response rate includes complete response and partial response defined by investigators according to RECIST 1.1or iRECIST criteria. |
| Secondary | Progression Free Survival (PFS) | Up to 2 years | Time from the date of first administration of the study drug to disease progression or death from any cause (any earliest date). |
| Secondary | Overall Survival (OS) | Up to 2 years | Time from the date of first administration of the study drug to the date of death. |
| Other | Immunological response (cytokines, lymphocyte phenotype) | Up to 120 days after the last dose of study drugs] | The concentration of cytokines (mainly include interleukin-2(IL-2), interleukin-6(IL-6),tumor necrosis factor α (TNF-α), the unit is picograms per milliliter) in tumor beds and peripheral blood and the changes of lymphocyte phenotype ( mainly include the number and percentage of cluster of differentiation 4(CD4+) and CD8+ T cells) following the treatment, will be assessed by quantitative polymerase chain reaction (qPCR) and flow cytometer. |
| Other | Biomarkers predictive of response and toxicity | Up to 120 days after the last dose of study drugs] | Biomarkers from tumor cells, lymphocytes and tumor microenvironment will be assessed for their potential in predicting clinical response and toxicity.All participants with treatment-related adverse events (AE) as assessed by National Cancer Institute Common Terminology Criteria for Adverse Event, Version 5.0(CTC AE 5.0). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06558773
GET https://conductscience.org/api/trials/v1/NCT06558773/registered